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repository@maastrichtuniversity.nl providing details and we will investigate your claim. Hypertension is a leading cause of morbidity and mortality, because it results in damage in several end organs, such as the kidneys, heart and brain. Hypertension is, besides age, the most important risk factor for haemorrhagic and ischemic stroke. In addition, hypertension is strongly associated with cerebral small vessel disease (cSVD). The term cSVD is used to describe all pathological processes that affect the small vessels of the brain. As these small brain vessels are difficult to visualize in vivo by standard imaging methods, the lesions that occur in the brain parenchyma due to cSVD have been accepted as imaging markers of cSVD. These lesions are preferably visualized by Magnetic Resonance Imaging (MRI) and include white matter hyperintensities (WMH), lacunes, cerebral microbleeds and perivascular spaces.
Multiple studies have focused on the implications of MRI markers of cSVD for cognitive performance or impairment. Most of these studies had a cross-sectional design and evidence is most convincing for associations between MRI markers and global cognitive function and the domains of processing speed and executive function. Fewer studies had a longitudinal design, so assessed the relation between MRI markers and cognitive decline.
These studies mostly focused on baseline presence of WMH and lacunes and showed associations with cognitive decline. Few longitudinal studies focused on progression of MRI markers over time and some of these studies showed associations between WMH progression and cognitive decline.
Although the evidence for a relationship between hypertension, cSVD and cognitive function, specifically for speed of mental processing and executive function, is quite strong, the degree of cSVD-related brain damage and cognitive problems greatly differs between hypertensive patients. This means that other factors also influence cSVD and cognitive function, or may moderate the relationship between hypertension, brain damage and cognitive function. More insight into predictors of cognitive performance and MRI markers of cSVD in hypertensive patients is important for identifying high-risk patients.
The general aim of this thesis was to determine predictors of cognitive function, cognitive decline and cSVD-related brain damage in patients with hypertension. We addressed the research objectives in a cohort of patients with essential hypertension who have been followed for a period of 9 years. For two research aims (chapter 6 and 7), a patient cohort with a broader spectrum of severity of cSVD was desired. Therefore, in addition to the patients with essential hypertension, we included hypertensive patients with a lacunar stroke.
In chapter 2 we investigated if subjective cognitive failures (SCF) are associated with objective cognitive function and/or MRI markers of cSVD in patients with hypertension. SCF are personal experiences of cognitive difficulties in everyday life and are easy to assess by 136 | Summary interview or questionnaire. While it might seem obvious that these subjective cognitive problems are indicative of lower objectively measured cognition, most previous research performed in other populations could not find this. We showed that SCF are associated with lower cognitive function and cerebral microbleeds, independent of potential confounders such as depression and anxiety. As it is an easy action to ask for cognitive difficulties in everyday life, this might be a first step in identifying patients with hypertension who are at high risk and may be in need of further examination.
In chapter 3 we investigated if compound scores of endothelial activation or inflammation, based on several blood markers, are associated with future cognitive performance.
Endothelial activation and inflammation have been suggested to play an important role in the pathogenesis of cSVD, but studies have been inconsistent on the association between individual blood markers and cognition. The use of a compound score of blood markers creates the possibility to draw more general conclusions about the underlying pathogenetic mechanisms leading to cognitive problems in hypertensive patients. We showed that a compound score of blood markers of endothelial activation, but not inflammation, was associated with lower cognitive performance three years later. This indicates that a process involving endothelial activation might play a role in the pathogenic pathways of cognitive problems in patients with hypertension.
The Framingham stroke risk profile (FSRP) is a well-known vascular risk score developed to predict clinical stroke in the individual. In chapter 4 we investigated if the FSRP at baseline is also associated with more 'silent' effects of cerebrovascular disease, namely with progression of MRI markers of cSVD and future cognitive performance. We showed that the FSRP was associated with progression of periventricular WMH and new microbleeds over 9 years. These associations lost significance after correction for the FSRP age component. In addition, the FSRP was associated with lower overall cognitive performance, which also applied to executive function, information processing speed and memory.
For executive function, the association with FSRP lost significance after adjustment for the age component. Our results showed that the FSRP is associated with progressive cSVD and lower future cognitive performance in patients with hypertension. However, for progressive cSVD, age seems to be the most important component. These results support the importance of early detection of other vascular risk factors in patients with hypertension. Clinicians should be aware of the entire risk factor profile in attempting to preserve cognitive performance.
In chapter 5 we investigated the implications of cardiac and renal organ damage, independent of brain damage, and of the combined presence of these sites of hypertensive organ damage for future cognitive function. We showed that presence of 2 or 3 sites of Summary | 137 organ damage compared to no organ damage was associated with lower cognitive performance 9 years later. In addition, we showed that cardiac damage, expressed as left ventricular mass index, was associated with future lower cognitive function independently of cSVD burden, while we could not show this association for renal damage. These results indicate that cardiac organ damage might be a marker of more severe hypertensive disease burden. In addition, it implicates that there should be awareness for cognitive function in patients with hypertensive cardiac organ damage.
Longitudinal studies have shown associations between baseline presence of MRI markers of cSVD and cognitive decline. However, most of these studies investigated individual MRI markers of cSVD, while in reality these MRI markers often co-occur in one patient.
To capture the total cSVD-related brain damage, a total cSVD score has been developed, which integrates all individual MRI markers into one measure. This score was shown to be associated with lower cognitive performance in cross-sectional studies, but was not applied before in longitudinal research. Therefore, in chapter 6 we investigated if the total cSVD score is predictive of future cognitive decline in patients with hypertension. We showed that the cSVD score was associated with decline in cognitive function over 4 years, specifically in executive function. These results emphasize the importance of considering total brain damage due to cSVD, instead of looking at individual MRI markers.
Only few longitudinal studies have investigated the association between progression of MRI markers of cSVD and cognitive decline. In addition, it is unclear whether baseline presence or progression of cSVD is more predictive of cognitive decline. Therefore, in chapter 7 we investigated the association between progression of MRI markers of cSVD and cognitive decline over 4 years and compared this with the association between baseline presence of the MRI markers and cognitive decline. We showed that progression of periventricular WMH over 4 years was associated with cognitive decline, while we could not show an association between baseline periventricular WMH and cognitive decline. We did not find significant associations between baseline presence or progression of the other MRI markers and cognitive decline. These results emphasize the importance of preventing progression of periventricular WMH in hypertensive patients.
In chapter 8 we discussed the findings of this thesis and three important questions that emerged from our results and other existing studies. First, we addressed the question how we can predict cognitive function, cognitive decline and cSVD-related brain damage in patients with hypertension in clinical practice. We reported several factors that could be used to identify high-risk patients, including SCF, the FSRP and the MRI total cSVD score.
Optimally, a compound risk score would be composed of these and other important predictors, to identify high-risk patients. Second, an important question is how we should 138 | Summary study the prevention of cognitive decline and dementia in patients with hypertension.
As previous randomized controlled trials (RCTs) are not conclusive about the effects of antihypertensive medications on preserving cognitive function, a well-performed RCT is needed. In such an RCT it is important that cognitive decline and incident dementia are the primary outcomes, in which these are determined with an extensive neuropsychological assessment covering different domains. In addition, as evidence is most conclusive about mid-life hypertension and late-life dementia, an RCT starting in mid-life with a long follow-up would be most likely to show positive results. Predictors of high risk of cognitive decline, such as the total cSVD score, could also be used as inclusion criteria for RCTs to increase the incidence of cognitive decline or dementia during follow-up. Lastly, we discussed new techniques for studying hypertensive organ damage of the brain. As conventional MRI cannot show microstructural brain damage and cerebrovascular functional alterations, other techniques might help to improve detection of hypertensive brain damage. These techniques include high-field MRI, diffusion tensor imaging and imaging of blood-brain barrier permeability. With these new imaging techniques, the detection of hypertensive brain damage could be improved, which should be used in further research to the consequences of such brain damage for cognitive function. 
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